Market Cap | 104.44M | P/E | - | EPS this Y | -130.90% | Ern Qtrly Grth | - |
Income | -35.39M | Forward P/E | 2.25 | EPS next Y | 132.60% | 50D Avg Chg | 3.00% |
Sales | 9.67M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 24.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -25.00% |
Recommedations | 1.60 | Quick Ratio | 3.68 | Shares Outstanding | 37.86M | 52W Low Chg | 149.00% |
Insider Own | 1.17% | ROA | -24.70% | Shares Float | 37.47M | Beta | 1.50 |
Inst Own | 36.96% | ROE | -46.12% | Shares Shorted/Prior | 0.99M/1.08M | Price | 2.86 |
Gross Margin | -55.83% | Profit Margin | - | Avg. Volume | 326,843 | Target Price | 6.50 |
Oper. Margin | -1,255.03% | Earnings Date | Nov 11 | Volume | 77,925 | Change | -2.05% |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Cantor Fitzgerald | Overweight | Apr 1, 24 |
Cantor Fitzgerald | Overweight | Aug 15, 23 |
Guggenheim | Buy | Apr 3, 23 |
Ladenburg Thalmann | Buy | Apr 3, 23 |
Guggenheim | Buy | Mar 1, 23 |
HC Wainwright & Co. | Buy | May 13, 22 |
HC Wainwright & Co. | Buy | Mar 31, 22 |
Aegis Capital | Buy | Jun 7, 21 |
Aegis Capital | Buy | Apr 12, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Taglietti Marco | Chief Executive Offi.. Chief Executive Officer | Apr 26 | Buy | 3.00 | 75,000 | 225,000 | 272,068 | 04/28/22 |
Sukenick Scott | General Counsel General Counsel | Apr 26 | Buy | 3.00 | 3,500 | 10,500 | 53,499 | 04/28/22 |
- | - - | Jan 26 | Sell | 7.98 | 599,000 | 4,780,020 | 1,800,000 | 01/26/21 |